HBOT vs low-level laser therapy as adjuncts

Do HBOT and LLLT treat the same problem after a hair transplant?

No. HBOT targets the post-transplant ischaemic window, supporting new grafts daily for about a week before they have their own blood supply. LLLT (photobiomodulation) targets existing follicles over months and is an established androgenetic alopecia treatment, not graft protection. They are treatments for different problems offered at the same time, not competing options.

Patients are often offered both hyperbaric oxygen and low-level laser therapy from the same menu of post-operative extras, which invites a direct comparison. The comparison is misleading unless you first separate what each one is actually for.

HBOT, in the post-transplant setting, is aimed at the ischaemic window: supporting grafts through the days before they have their own blood supply. It is delivered daily for about a week and then stopped.

LLLT, also called photobiomodulation or red light therapy, is aimed at stimulating existing follicles over months. Its established use is as a treatment for androgenetic alopecia — the native hair — rather than as protection for new grafts.

So they are not competing solutions to one problem. They are treatments for different problems, one of which happens to be offered at the same moment.

How does the evidence base for LLLT compare with HBOT's?

LLLT's evidence includes multiple randomised trials, including a 2025 meta-analysis of seven trials finding greater density and diameter gains when combined with Minoxidil. HBOT's entire hair-specific literature is one 34-patient trial, a five-patient case report, a nine-volunteer pilot study, and one letter to the editor — a far smaller base by volume.

LLLT

Low-level laser therapy for androgenetic alopecia has been studied in multiple randomised trials and has been the subject of meta-analyses. A 2025 systematic review and meta-analysis of seven randomised trials by Mawu and colleagues found that combining LLLT with topical Minoxidil produced a greater increase in hair density and diameter than Minoxidil alone, with comparable safety.

That is a real evidence base. It concerns treating androgenetic alopecia, and it is generally reported alongside or in combination with Minoxidil rather than as a standalone equivalent to medication.

HBOT

The entire hair-specific clinical literature on hyperbaric oxygen consists of one randomised trial of 34 patients, a five-patient case report, one preliminary study in nine healthy volunteers, and a letter to the editor. The trial found reduced early shedding (27.6% versus 69.1%) and less itching and folliculitis (11.8% versus 35.3%), with survival at nine months of 96.9% versus 93.8% and no statistically significant difference.

By volume of evidence, this is not a close comparison.

Does the larger LLLT evidence base mean it's proven to protect grafts?

No. LLLT's trials show it helps androgenetic alopecia, not that it protects transplanted grafts — a different claim. For the specific question of improving graft survival, neither has demonstrated an effect: HBOT has one small trial with a null result, while most of the larger LLLT literature does not address graft survival at all.

The LLLT literature is not evidence that LLLT protects grafts. It is evidence that LLLT can help androgenetic alopecia. Those are different claims, and the transfer between them is not automatic.

For the specific question 'does this adjunct improve the survival of transplanted follicles', the honest answer for both treatments is that it has not been demonstrated. HBOT has one small trial with a null result on that endpoint. LLLT has a larger literature that mostly does not address the endpoint at all.

This is the pattern across post-transplant adjuncts generally: a real evidence base for a related indication gets presented as evidence for the transplant application, and the gap between them is not mentioned.

What are the practical differences between HBOT and LLLT?

HBOT requires daily clinic attendance for six or seven days (60-90 minutes each) and carries barotrauma and confinement risks; LLLT is a home device used briefly over months with a safety profile comparable to control. HBOT is a one-week paid course; LLLT is an ongoing, usually one-off-purchase commitment that also protects your thinning native hair.

• Burden. HBOT requires daily attendance at a facility for six or seven days at 60-90 minutes a session. LLLT is typically a home device used for minutes at a time over months. If you are travelling for surgery, that difference is decisive.
• Duration. HBOT is a one-week intervention. LLLT is an ongoing commitment measured in months or years.
• Cost structure. HBOT is a course of paid sessions. LLLT is usually a one-off device purchase.
• Risk. HBOT carries barotrauma, oxygen toxicity and confinement anxiety risks and requires contraindication screening. LLLT's adverse effect profile in the trials is generally comparable to control.
• What they protect. LLLT is aimed at your native hair, which continues to thin after surgery unless it is treated. HBOT does nothing for that.

If you can only choose one, HBOT or LLLT, which should you pick?

Neither — that framing is wrong. What most reliably spoils a five-year result is continued loss of native hair around the grafts, not graft survival, and ongoing therapy like LLLT addresses that; HBOT does not. Between a week of chamber sessions and treating your remaining hair, the second is the better-evidenced spend.

For most patients this is the wrong framing, and the more useful question is what each is for.

The problem that most reliably ruins a hair transplant result over five years is not graft survival — it is continued loss of the native hair around the grafts. That is what medical therapy addresses, and it is the area where the evidence is strongest. LLLT belongs to that category of ongoing treatment; HBOT does not address it at all.

If the choice is genuinely between paying for a week of chamber sessions and paying for something that treats your remaining hair, the second is the better-evidenced use of the money. Discuss any medical therapy with a doctor who knows your history.

Sources

1. Mawu FO, et al. Comparative efficacy and safety of low-level laser therapy and topical Minoxidil combination vs. topical Minoxidil monotherapy for androgenetic alopecia: a systematic review and meta-analysis. Lasers in Medical Science, 2025;40(1):338. pubmed.ncbi.nlm.nih.gov/40826200
2. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
3. Giardiello F, De Medeiros Quirino L, Brigante R, Chumak M. Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation. Cureus, 2025;17(12):e99635. doi.org/10.7759/cureus.99635
4. Lee HY, Lee JY, Kim SC, Lee Y. Preliminary Effects of Hyperbaric Oxygen Therapy on Hair Follicle Characteristics in Healthy Subjects. Bioengineering, 2026;13(2):240. doi.org/10.3390/bioengineering13020240
5. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plastic and Reconstructive Surgery, 2011;127 Suppl 1:131S-141S. pubmed.ncbi.nlm.nih.gov/21200283

This article summarises published research and standard clinical practice. It is general educational information, not medical advice, and it does not replace the instructions your own surgical team gives you. Where their guidance differs from anything here, follow theirs.